Our group proposed that a standing committee of the National Multiple Sclerosis Society (NMSS) be formed to consider, prospectively, therapeutic agents for active trial in multiple sclerosis (MS). The committee members should represent various geographic areas, including Europe and Canada, and should probably include (along with neurologists) experts in rheumatology, oncology, pharmacology, and, possibly, virology and immunology.
It seemed important, for two reasons, to charge the recommended committee with concern for symptomatic therapies as well as those aimed at the disease process itself. First, such remedies may greatly improve the quality of life even if the disease process is not terminated. Second, the search for improved symptomatic therapies is more likely in the short run to alleviate suffering in patients with MS, indicating to them that concern for them is real.The symptomatic therapies to be considered include new antispastic agents, nerve conduction-enhancing drugs, antiataxic agents, and
Johnson KP, Santos GW. Choice of Therapeutic Agents for Trial. Arch Neurol. 1983;40(11):695–696. doi:10.1001/archneur.1983.04050100035012
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: